{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T17:07:59Z","timestamp":1794244079840,"version":"4.9.0"},"reference-count":15,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2025,12,20]],"date-time":"2025-12-20T00:00:00Z","timestamp":1766188800000},"content-version":"vor","delay-in-days":1859,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2020,11,17]],"date-time":"2020-11-17T00:00:00Z","timestamp":1605571200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,2,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>Wild type transthyretin amyloidosis (ATTRwt) has gained interest during recent years due to better diagnostic tools and the emergence of treatment options. Little is known about the prevalence of the disease. We aimed to investigate the prevalence in a heart failure population with myocardial hypertrophy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and results<\/jats:title>\n                    <jats:p>All patients with an ICD code of heart failure living within the catchment area of Ume\u00e5 University hospital and intraventricular septum &amp;gt;14 mm were offered screening with 3,3-diphosphono-1,2-propanodicarboxylic acid (DPD) scan and a clinical work up. Out of 2238 patients with heart failure, 174 patients were found to have a septum &amp;gt;14 mm. Ten patients were already diagnosed with hereditary ATTR cardiomyopathy, 12 patients had ATTRwt cardiomyopathy, 12 patients had known HCM, one patient had AL amyloidosis, and four patients had already undergone a negative DPD scan (DPD uptake grade 0 and 1) within the last 3 years. This left 134 patients who we tried to contact for screening, but 48 patients had either died or declined to participate. Out of 86 screened patients, 13 had a DPD uptake of grade 2 or 3 without other amyloid disease making the total number of patients with ATTRwt in this population 25.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Approximately 20% of investigated patients in a cohort with heart failure and increased myocardial wall thickness has ATTRwt. Calculated for the whole population of heart failure patients, the prevalence is just over 1.1%. Comparing this number to the total population would give an estimated prevalence of 1:6000.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/ehf2.13110","type":"journal-article","created":{"date-parts":[[2020,11,18]],"date-time":"2020-11-18T02:47:44Z","timestamp":1605667664000},"page":"745-749","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":77,"title":["Prevalence of Wild Type Transtyrethin Cardiac Amyloidosis in a Heart Failure Clinic"],"prefix":"10.1093","volume":"8","author":[{"given":"Krister","family":"Lindmark","sequence":"first","affiliation":[{"name":"Heart Centre, Department of Public Health and Clinical Medicine, Ume\u00e5 University , Ume\u00e5 ,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bj\u00f6rn","family":"Pilebro","sequence":"additional","affiliation":[{"name":"Heart Centre, Department of Public Health and Clinical Medicine, Ume\u00e5 University , Ume\u00e5 ,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Torbj\u00f6rn","family":"Sundstr\u00f6m","sequence":"additional","affiliation":[{"name":"Diagnostic Radiology, Department of Radiation Sciences, Ume\u00e5 University , Ume\u00e5 ,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Per","family":"Lindqvist","sequence":"additional","affiliation":[{"name":"Heart Centre, Department of Surgery and Perioperative Sciences, Ume\u00e5 University , Ume\u00e5 ,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2020,11,17]]},"reference":[{"key":"2026012114033951100_ehf213110-bib-0001","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1080\/13506129.2017.1286580","article-title":"The Swedish landscape of hereditary ATTR amyloidosis","volume":"24","author":"Suhr","year":"2017","journal-title":"Amyloid"},{"key":"2026012114033951100_ehf213110-bib-0002","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.jacc.2016.03.596","article-title":"Genotype and Phenotype of Transthyretin Cardiac Amyloidosis: THAOS (Transthyretin Amyloid Outcome Survey)","volume":"68","author":"Maurer","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"2026012114033951100_ehf213110-bib-0003","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.113.000098","article-title":"Senile systemic amyloidosis: clinical features at presentation and outcome","volume":"2","author":"Pinney","year":"2013","journal-title":"J Am Heart Assoc"},{"key":"2026012114033951100_ehf213110-bib-0004","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/j.pcad.2009.11.007","article-title":"Amyloid heart disease","volume":"52","author":"Falk","year":"2010","journal-title":"Prog Cardiovasc Dis"},{"key":"2026012114033951100_ehf213110-bib-0005","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1016\/j.jacc.2005.05.073","article-title":"Noninvasive etiologic diagnosis of cardiac amyloidosis using 99mTc-3,3-diphosphono-1,2-propanodicarboxylic acid scintigraphy","volume":"46","author":"Perugini","year":"2005","journal-title":"J Am Coll Cardiol"},{"key":"2026012114033951100_ehf213110-bib-0006","doi-asserted-by":"crossref","first-page":"2404","DOI":"10.1161\/CIRCULATIONAHA.116.021612","article-title":"Nonbiopsy diagnosis of cardiac transthyretin amyloidosis","volume":"133","author":"Gillmore","year":"2016","journal-title":"Circulation"},{"key":"2026012114033951100_ehf213110-bib-0007","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1056\/NEJMoa1805689","article-title":"Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy","volume":"379","author":"Maurer","year":"2018","journal-title":"N Engl J Med"},{"key":"2026012114033951100_ehf213110-bib-0008","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1136\/heartjnl-2012-302353","article-title":"Relative apical sparing of longitudinal strain using two-dimensional speckle-tracking echocardiography is both sensitive and specific for the diagnosis of cardiac amyloidosis","volume":"98","author":"Phelan","year":"2012","journal-title":"Heart"},{"key":"2026012114033951100_ehf213110-bib-0009","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1093\/eurheartj\/ehm342","article-title":"Classification of the cardiomyopathies: a position statement from the European Society Of Cardiology Working Group on Myocardial and Pericardial Diseases","volume":"29","author":"Elliott","year":"2008","journal-title":"Eur Heart J"},{"key":"2026012114033951100_ehf213110-bib-0010","doi-asserted-by":"crossref","first-page":"2585","DOI":"10.1093\/eurheartj\/ehv338","article-title":"Wild-type transthyretin amyloidosis as a cause of heart failure with preserved ejection fraction","volume":"36","author":"Gonzalez-Lopez","year":"2015","journal-title":"Eur Heart J"},{"key":"2026012114033951100_ehf213110-bib-0011","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1136\/hrt.27.5.711","article-title":"Senile cardiac amyloidosis","volume":"27","author":"Pomerance","year":"1965","journal-title":"Br Heart J"},{"key":"2026012114033951100_ehf213110-bib-0012","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0143456","article-title":"Amyloid cardiomyopathy in hereditary transthyretin V30M amyloidosis\u2014impact of sex and amyloid fibril composition","volume":"10","author":"Arvidsson","year":"2015","journal-title":"PLoS ONE"},{"key":"2026012114033951100_ehf213110-bib-0013","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1002\/ejhf.1563","article-title":"Real-world versus trial patients with transthyretin amyloid cardiomyopathy","volume":"21","author":"Canepa","year":"2019","journal-title":"Eur J Heart Fail"},{"key":"2026012114033951100_ehf213110-bib-0014","article-title":"A systematic approach for introduction of novel treatments to a chronic patient group: sacubitril-valsartan as a case study","author":"Norberg","year":"2020","journal-title":"Eur J Clin Pharmacol"},{"key":"2026012114033951100_ehf213110-bib-0015","doi-asserted-by":"crossref","first-page":"E141","DOI":"10.1002\/ajh.25440","article-title":"Monoclonal gammopathy plus positive amyloid biopsy does not always equal AL amyloidosis","volume":"94","author":"Sidiqi","year":"2019","journal-title":"Am J Hematol"}],"container-title":["ESC Heart Failure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ehf2.13110","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/ehf2.13110","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/eschf\/article-pdf\/8\/1\/745\/65798898\/eschf_8_1_745.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eschf\/article-pdf\/8\/1\/745\/65798898\/eschf_8_1_745.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T19:03:51Z","timestamp":1769022231000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eschf\/article\/8\/1\/745\/8369285"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,17]]},"references-count":15,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,11,17]]},"published-print":{"date-parts":[[2021,2,1]]}},"URL":"https:\/\/doi.org\/10.1002\/ehf2.13110","relation":{},"ISSN":["2055-5822"],"issn-type":[{"value":"2055-5822","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,2]]},"published":{"date-parts":[[2020,11,17]]},"assertion":[{"value":"2020-05-13","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-10-28","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-11-17","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}